Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.
Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting ...
Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in ...
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and ...
When bacteria cells replicate, they do so a little differently than human cells do. They don't undergo mitosis, a splitting that involves construction of spindles to carefully separate the DNA after ...
The war in Iran is exposing the world’s reliance on fragile fossil fuel routes, lending urgency to calls for hastening the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results